

## Pain



"Well, I guess that explains the abdominal pains."

## Pain



"Well, I guess that explains the abdominal pains."

**"Pain is a component of virtually all clinical strategies, and management of pain is a primary clinical imperative. Opioids are a mainstay of pain treatment."**

Goodman & Gilman, 12<sup>th</sup> edition

## Pain



"Well, I guess that explains the abdominal pains."

**"Pain is a component of virtually all clinical strategies, and management of pain is a primary clinical imperative. Opioids are a mainstay of pain treatment."**

Goodman & Gilman, 12<sup>th</sup> edition

Opioid ~~Analgesics~~  
Addiction



## Opioid ~~Analgesics~~ Addiction



*The Dividend, 1916*



*January 26, 2013 • New York Times*

# Opioid ~~Analgesics~~ Addiction

HEALTH

## *C.D.C. Painkiller Guidelines Aim to Reduce Addiction Risk*

By SABRINA TAVERNISE MARCH 15, 2016



WASHINGTON — In an effort to curb what many consider the **worst public health drug crisis in decades**, the federal government on Tuesday published the first national standards for prescription painkillers, recommending that doctors try pain relievers like ibuprofen before prescribing the highly addictive pills, and that they give most patients only a few days' supply.

New York Times, March 2016

# Opioid ~~Analgesics~~ Addiction

## Young Victims of the Opioid Epidemic

By THE EDITORIAL BOARD JAN. 16, 2017



Lilli Carré

New York Times, January 2017

# Opioid ~~Analgesics~~ Addiction

Young Victims of the Opioid Epidemic

---

By THE EDITORIAL BOARD JAN. 16, 2017


‘I couldn’t manage the pain’

‘This compound is very sneaky’

‘I believed the doctors would know better’

New York Times, January 2017






## Opioid ~~Analgesics~~ Addiction

In 2014, for the first time in Virginia, more people died from opioid overdoses than fatal car accidents.





## Opioid ~~Analgesics~~ Addiction

three Virginians die from drug overdose and more than two dozen are being seen in emergency departments every day due to drug overdose.



# Opioid ~~Analgesics~~ Addiction

## Young Victims of the Opioid Epidemic

---

By THE EDITORIAL BOARD JAN. 16, 2017

### ‘We need them’

The reporting is one-sided and leaves out how all of these new laws affect chronic-pain patients. We do not abuse these drugs. We need them to function in daily life. Politicians should not make health care decisions. —


**Christiane Warren**, Kearny, N.J.

New York Times, January 2017

Opioid ~~Analgesics~~  
Addiction




## Neurons & Activity




## Neurons & Activity

### A. Neuronal Communication



### B. Body Parts



## **“Opioid” Analgesics**




*Papaver somniferum*

- “opiate”: compounds structurally related to products found in opium.
  - natural plant alkaloids
  - semi-synthetic derivatives
  - endogenous peptides (e.g. endorphins)
- “opioid”: any substance, regardless of structure that has functional/pharmacological properties of an opiate.
- “narcotic”: derived from Greek word *narkotikos* for numbing or stupor. Word now associated with opiates and often used in legal contexts.

## Pain

- pain: perception of aversive/unpleasant sensation.
- nociception: transmission of signals to CNS that provide info about tissue damage.



- pains
  - acute nociception
  - tissue injury
    - factors released in injury site (e.g. prostaglandins, bradykinin, etc) activate Aδ fibers
    - hyperalgesia (mildly warm water on a sunburn)
  - nerve injury
    - may involve low-threshold afferents (i.e. Aβ fibers)



## Opioids & Receptors



2

### Endogenous Opioids

- 3 primary families:
  - endorphins
    - major peptide:  $\beta$ -endorphin
    - precursor: prepro-opiomelanocortin (POMC)
  - enkephalins
    - major peptides: met-enkephalin & leu-enkephalin
    - precursor: proenkephalin
  - dynorphins
    - major peptides: dynorphin A, dynorphin B & neoendorphin
    - precursor: prodynorphin



3

### Receptors

- 3 receptor types (all GPCRs):
  - $\mu$  (MOR)
  - $\delta$  (DOR)
  - $\kappa$  (KOR)
- Widely distributed in the CNS
  - Not surprising considering profound effects opioids have on CNS function

## Receptor Distribution Forebrain

### Receptors

Region	$\mu$		$\kappa$		$\delta$	
	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron
<b>Prefrontal cortex</b>						
Layer I	0	0	0	0	0	0
Layer II	0	0	++	++	++	+
Layer III	++	++	++	++	++	++
Layer IV	++	++	0	0	++	++
Layer V	++	++	++	++	++	+
Layer VI	++	++	++	++	+	++
<b>Occipital cortex, area 17</b>						
Layer I	0	0	0	0	0	0
Layer II	+	+	+	++	++	+
Layer III	+	+	+	+	++	+
Layer IV	+	+	0	0	++	+
Layer V	0	0	++	++	++	++
Layer VI	0	0	++	+	++	++
<b>Hippocampus</b>						
Dentate gyrus	++	+	++	++	++	++
CA1	++	++	+	++	+	++
CA2	++	++	+	++	++	++
CA3	++	++	++	++	+	++
CA4	++	++	+	++	+	+
<b>Striatum</b>						
Accumbens nucleus	++	++	++	++	++	++
Putamen anterior part	++	++	++	++	++	++
Putamen posterior part	++	++	++	++	++	++
Caudate nucleus anterior part	++	++	++	++	++	++
Caudate nucleus posterior part	++	++	++	++	++	++
Ventral pallidum	++	++	++	++	++	++
Globus pallidus external	++	++	0	0	++	++
Globus pallidus internal	+	+	0	0	0	0
Clastrum	+	+	++	++	0	0
Basal nucleus of Meynert	++	++	0	0	0	0

Peckys & Landwehrmeyer, 1999



## Receptor Distribution Midbrain

### Receptors

$\mu$

$\kappa$

$\delta$

Region	$\mu$		$\kappa$		$\delta$	
	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron
Substantia nigra						
Pars compacta	++ <sup>†</sup>	+++	+++ <sup>‡</sup>	+++ <sup>†††</sup>	0	0
Pars reticulata	+	++ <sup>††</sup>	+	+	0	0
Central inferior collicular nucleus	+++ <sup>†††</sup>	+++ <sup>†††</sup>	0	0	0	0
Periaqueductal gray	+++	+++ <sup>†††</sup>	+++ <sup>†††</sup>	+++	0	0
Trochlear nerve nucleus	0	0	+	++	0	0
Pontine nuclei	0	0	+++ <sup>†</sup>	++	+++ <sup>†</sup>	++
Tegmental pedunculopontine nucleus	+++ <sup>†††</sup>	+++ <sup>†††</sup>	0	0	0	0
Locus coeruleus	0	0	0	0	0	0
Pigmented neurons						
Pars alpha	+++ <sup>†</sup>	+++	++ <sup>†</sup>	+++	0	0
Reticular formation						
Ogancocellular nucleus	0	0	++ <sup>††</sup>	++ <sup>††</sup>	0	0
Reticular pontine nuclei	+++	+++	+	+	0	0
Lateral lemniscal nucleus	++	+++ <sup>†††††</sup>	++	++	0	0
Raphe nuclei	++	+++	+++	+++ <sup>†††</sup>	0	0
Parabrachial nucleus	+++	+++	0	0	0	0
Paralemniscal nucleus	+++ <sup>†††</sup>	+++ <sup>†††</sup>	0	0	0	0
Dorsal vagal nerve nucleus	+++ <sup>†††</sup>	+++ <sup>†††</sup>	++ <sup>††</sup>	++	+	+
Solitary tract nucleus	+++	+++ <sup>†††</sup>	++	+++	+	+
Gracile nucleus	0	0	+	+	+	+
Cuneate nucleus	0	0	0	0	+	++
Spinal tract trigeminal nerve nucleus	+++ <sup>†</sup>	+++ <sup>†††††</sup>	+++ <sup>†</sup>	+++	+++	++
Ambiguous nucleus	+++ <sup>†</sup>	+++	+++ <sup>†</sup>	+++	+	+
Retroambiguous nucleus	++	+++	0	0	0	0
Inferior olivary nucleus	+	++ <sup>††</sup>	0	0	0	0
Medial accessory olivary nucleus	+	++ <sup>††</sup>	0	0	0	0
Arcuate nucleus	0	0	+++ <sup>†</sup>	+++ <sup>†††</sup>	+++ <sup>†</sup>	+++ <sup>†††</sup>
Supraspinal nucleus	0	0	++	+++	0	0
Accessory nucleus	++	+++ <sup>†††</sup>	0	0	0	0
Cerebellum						
Granular layer	+++ <sup>†</sup>	++	+++	++	0	0
Golgi cells	+++ <sup>††††</sup>	+++ <sup>†††</sup>	+++ <sup>†††</sup>	+++ <sup>†††</sup>	+++ <sup>†††</sup>	+++ <sup>††</sup>

Peckys & Landwehrmeyer, 1999



# Receptor Distribution Spinal Cord

Region	Receptors					
	$\mu$		$\kappa$		$\delta$	
	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron	Density of labelled neurons	Grain density per labelled neuron
Dorsal horn	+++	++	+	+++	0	0
Substantia gelatinosa	++++	++	+++	+++	0	0
Zona intermedia	+	+++	+	+	0	0
Ventral horn	+	+	+	+	0	0

Peckys & Landwehrmeyer, 1999



## Opioids & Receptors



2

### Endogenous Opioids

- 3 primary families:
  - endorphins
    - major peptide:  $\beta$ -endorphin
    - precursor: pro-opiomelanocortin (POMC)
  - enkephalins
    - major peptides: met-enkephalin & leu-enkephalin
    - precursor: proenkephalin
  - dynorphins
    - major peptides: dynorphin A, dynorphin B & neoendorphin
    - precursor: prodynorphin



3

### Receptors

- 3 receptor types (all GPCRs):
  - $\mu$  (MOR) – target of most opiates, natural & synthetic
  - $\delta$  (DOR)
  - $\kappa$  (KOR)
- Widely distributed in the CNS
  - Not surprising considering profound effects opioids have on CNS function



## Opioids & Receptors

### Endogenous Opioids

Opioid	Receptor		
	$\mu$	$\delta$	$\kappa$
$\beta$ -endorphin	+++	+++	
met-enkephalin	++	+++	
leu-enkephalin	++	+++	
dynorphin A	++		+++
dynorphin B	+		+++

# Opioids & Receptors

## Common Opioid Analgesics

Opioid	$\mu$	$\delta$	$\kappa$
Morphine	+++		+
Hydromorphone	+++		
Oxymorphone	+++		
Methadone	+++		
Meperidine	+++		
Fentanyl	+++		
Sufentanil	+++	+	+
Alfentanil	+++		
Remifentanyl	+++		
Levorphanol	+++		
Codeine	+/-		
Hydrocodone	+/-		
Oxycodone	++		
Pentazocine	+/-		+
Nalbuphine	-		++
Buprenorphine	+/-	-	-
Butorphanol	+/-		+++

# Morphine



## Summary

- Decreases pain but highly addictive (addiction potential similar to that of heroin)
- $\mu$  (MOR) – target of most opiate analgesics
- MORs expressed in the periaqueductal gray (PAG)
- MORs expressed in the spinal cord


*"The analgesic actions of opiates after systemic delivery are believed to represent actions in the brain, spinal cord, & in some instances in the periphery."*

- Goodman & Gilman




## Periaqueductal Gray (PAG)

- mesencephalic structure
- projects to rostral ventromedial medulla
  - constitutes essential neural circuit for opioid-based analgesia
- high density of MORs
- administration of opioids directly into PAG blocks nociceptive responses in all animals (rodents to primates)
  - naloxone blocks response
- direct electrical stimulation of PAG produces analgesia




## Mechanisms of Opiate Analgesia




[Neuroscience Online: UT Health Center](#)

## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia

### Scenario #1




## Mechanisms of Opiate Analgesia

### Scenario #2



## Mechanisms of Opiate Analgesia



***But what's the point?***


*Neurons Do Not Require  
Synaptic Excitation to Turn On*

*Removal of Inhibition (Dis-inhibition)  
Can Also Turn Neurons On*







## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia



## Mechanisms of Opiate Analgesia




## Mechanisms of Opiate Analgesia



- 1) Positive change in voltage opens calcium channels
- 2) Calcium influx triggers vesicle release
- 3) Opening potassium channels causes negative change in voltage
- 4) Negative change in voltage: calcium channels *less* likely to open.

## Mechanisms of Opiate Analgesia



# Opioids & Receptors

## Common Opioid Analgesics

### Opioid

Morphine Hydromorphone Oxymorphone Methadone Meperidine Fentanyl Sufentanil Alfentanil Remifentanyl Levorphanol	Strong Agonists
Codeine Hydrocodone Oxycodone	Mild to Moderate Agonists
Pentazocine Nalbuphine Buprenorphine Butorphanol	Mixed Actions



Lange, 12<sup>th</sup> Edition





## Physiological Effects of Morphine

- **CNS Effects**

- **Analgesia**

- both sensory & emotional components

- **Euphoria**

- **Sedation**

- more common in the elderly
    - more common with the phenanthrenes (codeine, hydrocodone)

- **Respiratory Depression**

- all opioid analgesics produce significant respiratory depression by inhibiting brainstem respiratory mechanisms
    - dose-dependent

- **Cough Suppression**

- codeine
    - suppresses cough reflex

- **Miosis**

- valuable for diagnosing overdose

- **Truncal Rigidity**

- **Nausea & Vomiting**

- **Temperature**

- opioids can produce either hyperthermia (MOR agonists) or hypothermia (KOR agonists)



## Physiological Effects of Morphine

- **Peripheral Effects**

- **Gastrointestinal**

- constipation
    - tolerance does not develop (i.e. effect does not diminish)

- **Biliary Tract**

- opioids contract biliary smooth muscle
    - can cause biliary colic

- **Renal**

- opioids depress renal function

- **Uterus**

- opioids may prolong labor

## *Clinical Uses of Morphine*



- **Clinical Use**

- **Analgesia**

- severe, constant pain usually relieved
    - sharp, intermittent pain less effectively controlled

- **Acute Pulmonary Edema**

- historically used to relieve dyspnea associated with pulmonary edema
    - HOWEVER, recent studies find little evidence in support of this use

- **Cough**

- Low dose oral morphine can significantly suppress chronic cough but side effect profile may limit widespread utility
    - Codeine & dextromethorphan: commonly prescribed antitussives
      - Recent studies suggest that these have little/no efficacy relative to placebo in humans with chronic cough

- **Diarrhea**

- **Shivering**

## Side Effects of Morphine



### 13 Respiratory depression

- Respiration rate is decreased
- Affects respiratory centers (medulla oblongata & pons)
  - morphine reduces  $\text{CO}_2$ -dependent activation of respiratory centers
- Dose threshold for analgesic & respiratory effects are the same
- Lethal effects of morphine due to respiratory arrest, hypoxia & cardiovascular collapse



### 14 Decreased gut motility (i.e. constipation)

- Inhibits output of the myenteric plexus (also called "Auerbach's" plexus)
- Reduces propulsive contractions of longitudinal muscles



### 15 Difficulty with urination

- Inhibits urinary voiding reflex
- Catheterization may be required after therapeutic doses of morphine




### 16 May cause orthostatic hypotension

- Morphine is a powerful depressant of the medullary vasomotor center
- Has relatively little effect on blood pressure when recumbant
- Can produce severe hypotension in patient who has lost blood


### ● Allergic reaction

## Differences Among the Major Opiates

### ● Potency



### ● Duration of Action




### Partial MOR agonists: Pentazocine & Buprenorphine

- Used to treat pain
- Less respiratory depression
  - Can antagonize respiratory depression produced by Fentanyl without completely reversing pain (Buprenorphine)
- But can cause hallucinations/nightmares (Pentazocine)

## Opiate Abuse

- Opiates have powerful effect on reward pathway
- Mechanism: increase dopamine release from the ventral tegmental area (VTA)



### ● Treatment

- Medically supervised withdrawal alone is often insufficient to prevent relapse
- Withdrawal symptoms:
  - Dysphoria, anxiety, restlessness, insomnia
  - High blood pressure, tachycardia, diarrhea



## Opiate Overdose

### ● Symptoms

- Very low respiratory rate
- Hypotension
- Hypothermia
- Pin-point pupils (except when hypoxia becomes severe)
- Coma

### ● Treatment

- Ventilation



23

- Naloxone (repeated, small IV doses)
  - Opiate receptor antagonist (MOR) ...or an inverse agonist?
  - Reverses all effects except those due to prolonged hypoxia
  - Has very little oral bio-availability
  - Short T<sub>1/2</sub>
- Naltrexone Comparison. Naltrexone:
  - Longer T<sub>1/2</sub>
  - Can be taken orally
  - Primarily used for long-term treatment of opioid addiction
- Nalmefene Comparison. Nalmefene:
  - Longer T<sub>1/2</sub>
  - Can be taken orally
  - Expensive
  - More universal antagonist: MOR, KOR, DOR
  - Primarily used for management of alcohol dependence

# Opioid ~~Analgesics~~ Addiction

## Young Victims of the Opioid Epidemic

By THE EDITORIAL BOARD JAN. 16, 2017



Lilli Carré

New York Times, January 2017



# Opioid ~~Analgesics~~ Addiction


## REPORT

### PAIN RESEARCH

## A nontoxic pain killer designed by modeling of pathological receptor conformations

V. Spahn,<sup>1,†</sup> G. Del Vecchio,<sup>1,†</sup> D. Labuz,<sup>1</sup> A. Rodriguez-Gaztelumendi,<sup>1</sup> N. Massaly,<sup>1,\*</sup> J. Temp,<sup>1</sup> V. Durmaz,<sup>2</sup> P. Sabri,<sup>2</sup> M. Reidelbach,<sup>2</sup> H. Machelska,<sup>1</sup> M. Weber,<sup>2,†</sup> C. Stein<sup>1,§</sup>

Indiscriminate activation of opioid receptors provides pain relief but also severe central and intestinal side effects. We hypothesized that exploiting pathological (rather than physiological) conformation dynamics of opioid receptor-ligand interactions might yield ligands without adverse actions. By computer simulations at low pH, a hallmark of injured tissue, we designed an agonist that, because of its low acid dissociation constant, selectively activates peripheral  $\mu$ -opioid receptors at the source of pain generation. Unlike the conventional opioid fentanyl, this agonist showed pH-sensitive binding, heterotrimeric guanine nucleotide-binding protein (G protein) subunit dissociation by fluorescence resonance energy transfer, and adenosine 3',5'-monophosphate inhibition in vitro. It produced injury-restricted analgesia in rats with different types of inflammatory pain without exhibiting respiratory depression, sedation, constipation, or addiction potential.



## Quiz



● opiate-free



● taking opiates for pain  
● never abused opiates



● dependent on opiates  
● currently under the influence of opiates



Naloxone

## Quiz



● opiate-free



● taking opiates for pain  
● never abused opiates



● dependent on opiates  
● ~~currently under the~~  
influence of opiates




Naloxone



Buprenorphine

# Summary



***suggested reading***

- **Basic & Clinical Pharmacology, 12<sup>th</sup> ed. (chapter 31)**  
Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor
- **Pharmacological Basis of Therapeutics, 12<sup>th</sup> ed. (Chapter 18)**  
Goodman & Gilman

*questions:*  
*markbeen@virginia.edu*

